AMELUZ (aminolevulinic acid hydrochloride) gel – full prescribing information (2026)

Government Record · Biofrontera Inc.; FDA-approved labeling via DailyMed (US NLM) · September 17, 2026

Biofrontera Inc. et al., 2026-09-17: US label for aminolevulinic acid gel (Ameluz) with red-light PDT, approved for actinic keratoses and superficial basal cell carcinoma – the agent actually approved for photodynamic treatment of skin cancer in the US.

AMELUZ, in combination with photodynamic therapy (PDT) using BF-RhodoLED® or RhodoLED® XL lamp, a narrowband, red light illumination source, is indicated for: lesion-directed and field-directed treatment of actinic keratoses (AKs) of mild-to-moderate severity on the face and scalp in adults. the treatment of superficial basal cell carcinoma (sBCC) in adults.

Section 1 (Indications and Usage)

Biofrontera Inc. et al., 2026-09-17: US label for aminolevulinic acid gel (Ameluz) with red-light PDT, approved for actinic keratoses and superficial basal cell carcinoma – the agent actually approved for photodynamic treatment of skin cancer in the US. C8 label record – skin. Country: USA. Approved agent: aminolevulinic acid HCl gel with BF-RhodoLED narrowband red light. Not methylene blue. Establishes that the clinical skin-cancer PDT record belongs to porphyrin precursors. Study type: regulatory record.